Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

PURPOSE: Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma. METHODS: Cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, was admin...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Batchelor, Tracy T., Duda, Dan G., di Tomaso, Emmanuelle, Ancukiewicz, Marek, Plotkin, Scott R., Gerstner, Elizabeth, Eichler, April F., Drappatz, Jan, Hochberg, Fred H., Benner, Thomas, Louis, David N., Cohen, Kenneth S., Chea, Houng, Exarhopoulos, Alexis, Loeffler, Jay S., Moses, Marsha A., Ivy, Percy, Sorensen, A. Gregory, Wen, Patrick Y., Jain, Rakesh K.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2010
Fag:
Original Reports
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2903316/
https://ncbi.nlm.nih.gov/pubmed/20458050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.26.3988
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker